State Street Corp Sells 53,915 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

State Street Corp lessened its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 1.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,204,718 shares of the company’s stock after selling 53,915 shares during the period. State Street Corp owned about 2.15% of Xeris Biopharma worth $9,133,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Xeris Biopharma during the third quarter valued at about $35,000. Quantbot Technologies LP acquired a new stake in shares of Xeris Biopharma during the third quarter worth $44,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Xeris Biopharma by 4,512.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock valued at $37,000 after buying an additional 15,929 shares during the last quarter. Asset Management Group Inc. increased its position in shares of Xeris Biopharma by 130.7% in the 2nd quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after acquiring an additional 15,000 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in Xeris Biopharma by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock worth $82,000 after acquiring an additional 11,239 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

XERS has been the topic of several research analyst reports. Piper Sandler downgraded Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research note on Monday, November 11th. HC Wainwright upped their target price on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th.

Xeris Biopharma Stock Performance

NASDAQ:XERS opened at $3.50 on Friday. The company has a fifty day moving average of $3.29 and a two-hundred day moving average of $2.81. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.69 and a fifty-two week high of $3.87. The stock has a market capitalization of $521.78 million, a PE ratio of -7.78 and a beta of 2.65.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.